ArticleJournal of clinical medicine2018
Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer's Disease
Article in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Relationship between acute glucose variability and cognitive decline in type 2 diabetes: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Trial
- Resveratrol and the neuroinflammation axis in Alzheimer's disease, Parkinson's disease, multiple sclerosis, and cerebral ischemia.Frontiers in immunology · 2026Review
- Resveratrol's Multifaceted Potential in Alzheimer's Disease: Insights from Preclinical and Clinical Evidence.Molecular neurobiology · 2025Review
- The Cognitive Restoration Effects of Resveratrol: Insight Molecular through Behavioral Studies in Various Cognitive Impairment Models.ACS pharmacology & translational science · 2024Review
- Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer's Disease Inflammation.Antioxidants (Basel, Switzerland) · 2024Article
- The Nrf2-HO-1 system and inflammaging.Frontiers in immunology · 2024Review
- Resveratrol: Protective Agent Against Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2024Review
- Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review.IET nanobiotechnology · 2023Review
- A Review on Phyto-Therapeutic Approaches in Alzheimer's Disease.Journal of functional biomaterials · 2023Review
- Tau Mediates Synergistic Influence of Vascular Risk and Aβ on Cognitive Decline.Annals of neurology · 2022Article
- In Silico Analysis of Metabolites from Peruvian Native Plants as Potential Therapeutics against Alzheimer's Disease.Molecules (Basel, Switzerland) · 2022Article
- Antioxidant Activity of Resveratrol Diastereomeric Forms Assayed in Fluorescent-Engineered Human Keratinocytes.Antioxidants (Basel, Switzerland) · 2022Article
- μ-Opioid Receptor-Mediated AT1R-TLR4 Crosstalk Promotes Microglial Activation to Modulate Blood Pressure Control in the Central Nervous System.Antioxidants (Basel, Switzerland) · 2021Article
- Impact of dietary polyphenols on neuroinflammation-associated disorders.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Microglia and modifiable life factors: Potential contributions to cognitive resilience in aging.Behavioural brain research · 2021Review
- A Mechanistic Evaluation of Antioxidant Nutraceuticals on Their Potential against Age-Associated Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2020Review
- Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders.Mechanisms of ageing and development · 2020Review
- Polyphenols as Caloric-Restriction Mimetics and Autophagy Inducers in Aging Research.Nutrients · 2020Review
- The role of resveratrol in bone marrow-derived mesenchymal stem cells from patients with osteoporosis.Journal of cellular biochemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
Recent studies have indicated that several anti-hypertensive drugs may delay the development and progression of Alzheimer's disease (AD). However, the relationships among AD, hypertension, and oxidative stress remain to be elucidated. Here, we aimed to determine whether reactive oxygen species (ROS) reduction by resveratrol in the brain leads to cognitive impairment reduction in rats with angiotensin II (Ang-II)-induced early AD. Male Wistar Kyoto (WKY) rats with Ang-II-induced AD were treated with losartan or resveratrol for two weeks. Our results show decreased blood pressure, increased hippocampal brain-derived neurotrophic factor (BDNF) level, and decreased nucleus tractus solitarius (NTS) ROS production in the Ang-II groups with losartan (10 mg/kg), or resveratrol (10 mg/kg/day) treatment. Furthermore, losartan inhibition of hippocampal Tau
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.